Peresolimab
Based on 2 publication(s) in Google Scholar
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis.
For research use only. We do not sell to patients.
- Purity: 99.62%
- CAS No.: 2411580-63-5
- Molecular Weight:145.16 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Peresolimab
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PDCD1/PD-1/CD279
In Vitro
Peresolimab is an agonist for PD-1 that binds to PD-1 receptor and activates PD-1 signaling pathway. Peresolimab inhibits T cell receptor (TCR) signals, inhibits the activation of T cells, thereby reducing inflammation and disease symptoms[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
-
Immobilized PD-1 Protein, Cynomolgus can bind Peresolimab. The EC50 for this effect is 7.388 ng/mL.
Chemical Information
-
CAS No. 2411580-63-5
-
Appearance Liquid
-
Molecular Weight 145.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Peresolimab]
-
Synonyms
LY-3462817
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Tuttle J, et al. Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. Reply. N Engl J Med. 2023 Jul 27;389(4):378-379. [Content Brief]
[2]. Leane CM, et al., PD-1 regulation of pathogenic IL-17-secreting γδ T cells in experimental autoimmune encephalomyelitis. Eur J Immunol. 2024 Oct;54(10):e2451212. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)